Lee Ainslie - Maverick Capital
Holding/activity history for Alnylam Pharmaceuticals (ALNY)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price |
| 2021 Q4 | 0 | 0 | Sell 100.00% | 0.01 | |
| 2021 Q3 | 3,983 | 0.01 | Reduce 98.64% | 0.72 | $188.80 |
| 2021 Q2 | 292,683 | 0.47 | Reduce 63.24% | 0.81 | $169.52 |
| 2021 Q1 | 796,234 | 1.05 | Reduce 19.12% | 0.25 | $141.19 |
| 2020 Q4 | 984,502 | 2.05 | Add 1.76% | 0.04 | $129.97 |
| 2020 Q3 | 967,461 | 2.62 | Reduce 13.12% | 0.40 | $145.60 |
| 2020 Q2 | 1,113,608 | 3.47 | Reduce 16.88% | 0.70 | $148.11 |
| 2020 Q1 | 1,339,705 | 3.08 | Reduce 40.74% | 2.12 | $108.85 |
| 2019 Q4 | 2,260,897 | 3.79 | Reduce 29.85% | 1.61 | $115.17 |
| 2019 Q3 | 3,222,813 | 3.81 | Reduce 23.92% | 1.20 | $80.42 |
| 2019 Q2 | 4,236,016 | 4.45 | Add 31.95% | 1.08 | $72.56 |
| 2019 Q1 | 3,210,387 | 3.98 | Add 14.50% | 0.50 | $93.45 |
| 2018 Q4 | 2,803,951 | 3.00 | Add 85.44% | 1.38 | $72.91 |
| 2018 Q3 | 1,512,064 | 1.65 | Add 121.92% | 0.91 | $87.52 |
| 2018 Q2 | 681,354 | 0.78 | Buy | 0.78 | $98.49 |